The Role of Dapagliflozin in Heart Failure

Various SGLT-2s have been shown to improve cardiovascular outcomes in the presence and absence of diabetes. A recent study evaluated the effect of dapagliflozin in mildly reduced or preserved ejection fraction. Join host, Geoff Wall, as he discusses how SGLT-2s may be a real GameChanger in heart failure with expert, Troy Lynn Lewis.The GameChangerThe data showcasing the benefits of SGLT-2s in patients with heart failure with or without diabetes continues to grow. Dapagliflozin may be another treatment option for persons with heart failure.Are you a CEimpact Member? Members get exclusive access to new courses and CE for this podcast. Over 62 hours of new CE each year + access to hundreds more on demand. Go to www.CEimpact.com to become a member today! Show Segments00:00 - Introductions01:55 - The DELIVER Study14:10 - GameChanger: DELIVER Discussion20:44 - Connecting to Practice: Patient Considerations26:11 - Closing RemarksHostGeoff Wall, PharmD, BCPS, FCCP, CGPProfessor of Pharmacy Practice, Drake UniversityInternal Medicine/Critical Care, UnityPoint HealthGuestTroy Lynn Lewis, PharmD, BC-ADMAssistant Professor, Pharmacy PracticeWilkes UniversityReferences and ResourcesDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection FractionRedeem your CPE or CME hereCPE (Pharmacist) CME (Physician) Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)Pharmacists: Get a membershipPrescribers: Get a membershipCE InformationLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the role of SGLT-2s in heart failure management2. Discuss the results of the DELIVER trial0.05 CEU/0.5 HrUAN: 0107-0000-22-414-H01-PInitial release date: 11/14/2022Expiration date: 11/14/2023Additional CPE and CME details can be found here.Follow CEimpact on Social Media:LinkedInInstagram